158 related articles for article (PubMed ID: 7248987)
1. Oral VP-16-213 in transitional cell carcinoma of the bladder: a phase II study.
Panduro J; Hansen M; Hansen HH
Cancer Treat Rep; 1981; 65(7-8):703-4. PubMed ID: 7248987
[No Abstract] [Full Text] [Related]
2. [Phase II study of etoposide (VP-16-213) in genitourinary tumors. VP-16-213 Genitourinary Study Group].
Suzuki K
Gan To Kagaku Ryoho; 1986 Sep; 13(9):2772-9. PubMed ID: 3753024
[TBL] [Abstract][Full Text] [Related]
3. Combination VM-26 and adriamycin for metastatic transitional cell carcinoma.
Rodriguez LH; Johnson DE; Holoye PY; Samuels ML
Cancer Treat Rep; 1977; 61(1):87-8. PubMed ID: 324624
[No Abstract] [Full Text] [Related]
4. [Effect of etoposide for pulmonary metastases from urogenital tract cancer].
Fujita K; Murayama T; Sayama T
Gan To Kagaku Ryoho; 1984 Nov; 11(11):2438-41. PubMed ID: 6497402
[TBL] [Abstract][Full Text] [Related]
5. [A phase II study of NK171 (etoposide)].
Kimura K; Niitani H
Gan To Kagaku Ryoho; 1985 Oct; 12(10):2011-7. PubMed ID: 2996442
[TBL] [Abstract][Full Text] [Related]
6. [Collaborative phase II study of etoposide (NK-171). Urological Cooperative Study Group of etoposide (NK-171)].
Gan No Rinsho; 1985 Jul; 31(8):944-52. PubMed ID: 4040986
[TBL] [Abstract][Full Text] [Related]
7. Multicenter Phase II trial of etoposide in refractory small cell lung cancer.
Issell BF; Einhorn LH; Comis RL; Lawson RD; Baker LH; Harvey HA; Lanzotti VA; Wampler GL; Daniels JR; Anderson PN
Cancer Treat Rep; 1985 Jan; 69(1):127-8. PubMed ID: 2981617
[No Abstract] [Full Text] [Related]
8. Phase II study of VP 16-213 (etoposide) in metastatic transitional cell urothelial cancer.
Ponder BA; Oliver RT
Cancer Chemother Pharmacol; 1984; 12(1):64-5. PubMed ID: 6690078
[TBL] [Abstract][Full Text] [Related]
9. Phase II clinical trial of weekly administration of VP-16-213 in small cell bronchogenic carcinoma.
Cohen MH; Broder LE; Fossieck BE; Ihde DC; Minna JD
Cancer Treat Rep; 1977; 61(3):489-90. PubMed ID: 194694
[No Abstract] [Full Text] [Related]
10. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.
Radice PA; Bunn PA; Ihde DC
Cancer Treat Rep; 1979 Aug; 63(8):1231-9. PubMed ID: 225026
[No Abstract] [Full Text] [Related]
11. Evidence for a schedule-dependent deleterious interaction between paclitaxel, vinblastine and cisplatin (PVC) in the treatment of advanced transitional cell carcinoma.
Mulatero C; McClaren BR; Mason M; Oliver RT; Gallagher CJ
Br J Cancer; 2000 Dec; 83(12):1612-6. PubMed ID: 11104554
[TBL] [Abstract][Full Text] [Related]
12. Teniposide in metastatic renal and bladder cancer: a Southwest Oncology Group Study.
Oishi N; Berenberg J; Blumenstein BA; Johnson K; Rivkin SE; Bukowski RM; O'Bryan RM; Stephens RL; Quagliana J; Saiers JH
Cancer Treat Rep; 1987 Dec; 71(12):1307-8. PubMed ID: 3690547
[No Abstract] [Full Text] [Related]
13. Phase II evaluation of VM-26 in patients with metastatic transitional cell carcinoma of the urinary tract: an Eastern Cooperative Oncology Group study.
Qazi R; Elson P; Khandekar JD
Cancer Treat Rep; 1982 Feb; 66(2):405-6. PubMed ID: 7055823
[No Abstract] [Full Text] [Related]
14. Palliative chemoirradiation for transitional carcinoma of the bladder: a case report.
Greenland JD; Bauman GS; Winquist E; Shepherd RR
Can J Urol; 2000 Aug; 7(4):1085-7. PubMed ID: 11109080
[TBL] [Abstract][Full Text] [Related]
15. Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agents.
Edmonson JH; Decker DG; Malkasian GD; Webb MJ; Jorgensen EO
Gynecol Oncol; 1978 Feb; 6(1):7-9. PubMed ID: 620951
[No Abstract] [Full Text] [Related]
16. [Use of VM-26 as a single agent in the treatment of transitional cell carcinoma of the urinary tract].
Aso Y; Ushiyama T; Suzuki K; Tajima A; Naide Y; Ohshima S; Matsuura O; Fukushima M; Ota K; Ono Y
Nihon Gan Chiryo Gakkai Shi; 1988 May; 23(5):1046-51. PubMed ID: 3418215
[No Abstract] [Full Text] [Related]
17. Phase II study of etoposide (VP-16) in the treatment of advanced head and neck cancer.
Grunberg SM; Felman IE; Gala KV; Johnson KB; Owens JC
Am J Clin Oncol; 1985 Oct; 8(5):393-5. PubMed ID: 4061373
[TBL] [Abstract][Full Text] [Related]
18. A combination of cyclophosphamide, methotrexate, vincristine and VP 16-213 (NSC 141 540) in the treatment of bronchogenic carcinoma.
Cavalli F; Hasler E; Ryssel HJ; Sonntag RW; Brunner KW
Tumori; 1977; 63(2):169-73. PubMed ID: 898287
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic factors of urinary bladder carcinoma].
vom Dorp F; Jaeger T; Schmidt K; Siffert W; Rübben H
Urologe A; 2007 Sep; 46(9):1151. PubMed ID: 17641868
[No Abstract] [Full Text] [Related]
20. Phase I study of VP-16-213 (Etoposide) administered as a continuous 5-day infusion.
Lokich J; Corkery J
Cancer Treat Rep; 1981; 65(9-10):887-9. PubMed ID: 7273024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
